Physician profile
Monica Smith
NPI 1346258795
$5,631.04
in general payments reported to CMS, 2019-2025
19 companies · $598 in 2025
The $598 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $41.35 · 2021: $787 · 2022: $1,445 · 2023: $1,102 · 2024: $1,436 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,025 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,024.65 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,066.63 | 2021-2024 | Vraylar |
| Janssen Pharmaceuticals, INC | $730.41 | 2020-2025 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $611.56 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $417.91 | 2021-2022 | |
| Alkermes, INC. | $398.53 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Supernus Pharmaceuticals, INC. | $390.05 | 2022-2024 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $365.68 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $313.50 | 2021-2025 | Caplyta |
| Indivior INC. | $306.98 | 2021-2025 | Perseris, Sublocade |
| Neurocrine Biosciences, INC. | $301.07 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $265.27 | 2021-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $165.30 | 2024-2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $58.17 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $55.74 | 2019-2024 | |
| Axsome Therapeutics, INC. | $44.16 | 2023 | Auvelity |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $40.28 | 2020-2024 | Secuado |
| Takeda Pharmaceuticals U.S.A., INC. | $40.22 | 2022 | |
| Shire North American Group INC | $33.75 | 2019 | |
| Allergan, INC. | $25.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.